BRCA1 and familial pancreatic carcinoma: Along with these studies, olaparib has also been approved as a maintenance drug, used in germline BRCA1/2 mutant advanced PDAC (pancreatic ductal adenocarcinoma) by the United States FDA as a phase III Pancreatic Cancer Olaparib Ongoing (POLO) trials have revealed that the administration of olaparib (as a maintenance treatment) magnified the progression-free survival (PFS) rate when compared to a placebo (Chi et al., 2021; Zhu et al., 2020).